Dr. Goldberg explains disparities in shared decision-making for prostate cancer screening
“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
Hanan Goldberg, MD, MSc, discusses the sociodemographic disparities found in his recent study on shared decision-making for prostate cancer screening, which was presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Goldberg is an assistant professor at SUNY Upstate Medical University in Syracuse, New York.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.
